Nexplanon 68 MG implants
Ended Awarded
- Contract number
- SPE2DR26FJUT1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $21,311
Award facts
- Contract value 100% obligated
- $21,311.10 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $21,311.10 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nexplanon 68 mg implants. This delivery order, awarded on November 18, 2025, with an ultimate completion date of December 10, 2025, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group is the sole awardee with no subcontractor relationships identified in the award documentation.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and a completion date of December 31, 2036. The PPV-G GEN V represents a comprehensive $30.3 billion acquisition strategy that authorizes DLA to issue firm fixed-price delivery orders for a full range of pharmaceutical products and medical consumables to support the recurring medical supply needs of military healthcare facilities worldwide. This delivery order for contraceptive implants exemplifies the diverse and specialized pharmaceutical requirements that DMS Pharmaceutical Group is positioned to fulfill as a critical supplier within the Department of Defense's global military medical system.
Quick answers
Who was awarded contract SPE2DR26FJUT1?
SPE2DR26FJUT1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 18, 2025.
How much is contract SPE2DR26FJUT1 worth?
The government has obligated $21,311 on SPE2DR26FJUT1.
Is contract SPE2DR26FJUT1 an order under another contract?
Yes. SPE2DR26FJUT1 is a delivery order under SPE2DR25D9329, an indefinite delivery contract.
Was contract SPE2DR26FJUT1 competed?
The extent of competition for SPE2DR26FJUT1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award